Molecular biology of esophageal squamous cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 33, Issue 2, 2000, Pages 71-90

  Lam, Alfred King Y ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Esophageal squamous carcinoma; Molecular biology; Review

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN D1; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATIN; NUCLEAR PROTEIN; PROTEIN P53;

APOPTOSIS; ARGYROPHILIA; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; EPSTEIN BARR VIRUS; ESOPHAGUS CARCINOMA; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENE; GEOGRAPHIC DISTRIBUTION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASM PROTEINS;

EID: 0033963695     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00054-2     Document Type: Review

References (206)

1. Pisani P., Parkin D.M., Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int. J. Cancer. 55:1993;891-903.
2. Whelan SL, Parkin DM, Masuyer E, et al. Histograms depicting rates of cancer age-standardized to the world population by site and sex, In: International Agency for Research on Cancer. Patterns of Cancer in Five Continents. Lyon: I.A.R.C. Scientific Publications No. 102, 1990.
3. Muñoz N. Epidemiological aspects of esophageal cancer. Endoscopy. 23:1993;609-612.
4. Reed P.I., Johnston B.J. The changing incidence of esophageal cancer. Endoscopy. 25:1993;606-608.
5. Coleman MP, Estève J, Damiecki P, et al. Esophagus. In: International Agency for Research on Cancer, Trends in cancer incidence and mortality. Lyon: I.A.R.C. Scientific Publications No. 121, 1993. p. 161-192.
6. Lam K.Y., Ma L. Pathology of esophageal cancers: local experience and current insights. Chin. Med. J. 110:1997;459-464.
7. Lam K.Y., Ma L.T., Wong J. Measurement of extent of spread of oesophageal squamous carcinoma by serial sectioning. J. Clin. Pathol. 49:1996;124-129.
8. Cheng K.K., Duffy S.W., Day N.E. et al. Esophageal cancer in never-smokers and never-drinkers. Int. J. Cancer. 60:1995;820-822.
9. Garidou A., Tzonou A., Lipworth L. et al. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int. J. Cancer. 68:1996;295-299.
10. Saegussa M., Hashimura M., Takano Y. et al. Absence of human papillomavirus genomic sequences detected by the polymerase chain reaction in esophageal and gastric carcinomas in Japan. J. Clin. Pathol. Mol. Pathol. 50:1997;101-104.
11. Mizobuchi S., Sakamoto H., Tachimori Y. et al. Absence of human papillomavirus-16 and -18 DNA and Epstein-Barr virus DNA in esophageal squamous cell carcinoma. Jpn. J. Clin. Oncol. 27:1997;1-5.
12. Shan L., Nakamura Y., Nakamura M. et al. Synchronous and metachronous multicentric squamous cell carcinomas in the upper aerodigestive tract. Pathol. Int. 47:1997;68-72.
13. Woo Y.J., Yoon H.K. In situ hybridization study on human papillomavirus DNA expression in benign and malignant squamous lesions of the esophagus. J. Korean Med. Sci. 11:1996;467-473.
14. Chang F., Syrjänen S., Shen Q. et al. Demonstration of human papillomavirus (HPV) type 30 in esophageal squamous cell carcinoma by in situ hybridization. Int. J. Cancer. 55:1993;171-173.
15. Chang F., Syrjänen S., Wang L. et al. p53 overexpression and human papillomavirus (HPV) infection in esophageal squamous cell carcinomas derived from a high-incidence area in China. Anticancer Res. 17:1997;709-716.
16. Lam K.Y., He D., Ma L. et al. Presence of human papillomavirus in esophageal squamous cell carcinomas of Hong Kong Chinese and its relationship with p53 gene mutation. Hum. Pathol. 28:1997;657-663.
17. Suzuk L., Noffsinger A.E., Hui Y.Z. et al. Detection of human papillomavirus in esophageal squamous cell carcinoma. Cancer. 78:1996;704-710.
18. He D., Zhang D.K., Lam K.Y. et al. Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int. J. Cancer. 72:1997;959-964.
19. Miller B.A., Davidson M., Myerson D. et al. Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska natives. Int. J. Cancer. 71:1997;218-222.
20. Rugge M., Bovo D., Busatto G. et al. p53 alternations but no human papillomavirus infection in preinvasive and advanced squamous esophageal cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 6:1997;171-176.
21. Bretagnol F., Bardaxoglou E., Causse X. et al. Esophageal squamous carcinoma associated with human papilloma virus infection. Dis. Esophagus. 9:1996;224-225.
22. West A.B., Soloway G.N., Lizarraga G. et al. Type 73 human papillomavirus in esophageal squamous cell carcinoma: a novel association. Cancer. 77:1996;2440-2444.
23. Paz I.B., Cook N., Odom-Maryon T. et al. Human papillomavirus (HPV) in head and neck cancer: an association of HPV16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 79:1997;595-604.
24. Turner J.R., Shen L.H., Crum C.P. et al. Low prevalence of human papillomavirus infection in esophageal squamous cell carcinomas from North America: analysis by a highly sensitive and specific polymerase chain reaction-based approach. Hum. Pathol. 28:1997;174-178.
25. Shibagaki I., Tanaka H., Shimada Y. et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin. Cancer Res. 1:1995;769-773.
26. Morgan R.J., Perry A.C.F., Newcomb P.V. et al. Human papillomavirus and esophageal squamous cell carcinoma in the UK. Eur. J. Surg. Oncol. 23:1997;513-517.
27. Kok T.C., Nooter K., Hung T.A. et al. No evidence of known types of human papillomavirus in squamous cell cancer of the esophagus in a low-risk area. Eur. J. Cancer. 33:1997;1865-1868.
28. Takahashi A., Ogoshi S., Ono H. et al. High-risk human papillomavirus infection and overexpression of p53 protein in squamous cell carcinoma of the esophagus from Japan. Dis. Esophagus. 11:1998;162-167.
29. Poljak M., Cerar A., Seme K. Human papillomavirus infection in esophageal carcinomas: a study of 121 lesions using multiple broad-spectrum polymerase chain reactions and literature review. Hum. Pathol. 29:1998;266-271.
30. Agarwai S.K., Chatterji A., Sharma B.K. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumor suppressor gene proteins in esophageal cancer. Indian J. Exp. Biol. 36:1998;559-563.
31. De Villiers E.M., Lavergne D., Chang F. et al. An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. Int. J. Cancer. 81:1999;225-228.
32. Lavergne D., De Villiers E.M. Papillomavirus in esophageal papillomas and carcinomas. Int. J. Cancer. 80:1999;681-684.
33. Benamouzig R., Pigot F., Quiroga G. Human papillomavirus infection in esophageal squamous-cell carcinoma in Western countries. Int. J. Cancer. 50:1992;549-552.
34. Fidalgo P.O., Cravo M.L., Chaves P.P. et al. High prevalence of human papillomavirus in squamous cell carcinoma and matched normal esophageal mucosa. Cancer. 76:1995;1522-1528.
35. Khurshid A, Kazuya N, HanaeI, et al. Infection of human papillomavirus (HPV) and Epstein-Barr virus (EBV) and p53 expression in human esophageal carcinoma, J Pak Med Assoc 1998;48:138-142.
36. Zur Hausen H., De Villiers E.M. Human papilloma virus. Annu. Rev. Microbiol. 48:1994;427-447.
37. Lam K.Y., Srivastava G., Leung M.L. et al. Absence of Epstein-Barr virus in oesophageal squamous cell carcinoma: a study of 74 cases using in-situ hybridization. J. Clin. Pathol. Mol. Pathol. 48:1995;M188-M190.
38. Jenkins T.D., Nakagawa H., Rustgi A.K. The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma. Oncogene. 13:1996;1809-1813.
39. Mori M., Watanabe M., Tanaka S. et al. Epstein-Barr virus-associated carcinomas of the esophagus and stomach. Arch. Pathol. Lab. Med. 118:1994;998-1001.
40. Nimura Y., Yokoyama S., Fujimori M. et al. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer. 80:1997;852-857.
41. Lin D.X., Tang Y.M., Peng Q. et al. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidmil. Biomarkers. 11:1997;1013-1018.
42. Moirta S., Yano M., Shiozaki H. et al. CYP1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous cell carcinoma of the esophagus. Int. J. Cancer. 71:1997;192-195.
43. Hori H., Kawano T., Endo M. et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol. 25:1997;568-575.
44. Lam K.Y., Loke S.L., Shen X.C. et al. Cytokeratin expression in non-neoplastic oesophageal epithelium and squamous cell carcinoma of the oesophagus. Virchows Arch. 426:1995;345-349.
45. Yamamoto K., Oka M., Hayashi H. et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 79:1997;1647-1655.
46. Wong F.H., Hu C.P., Chiu J.H. et al. Expression of multiple oncogenes in human esophageal carcinomas. Cancer Invest. 12:1994;121-131.
47. Jones G.J., Heiss N.S., Veale R.B. et al. Amplification and expression of the TGF-α, EGF receptor and c-myc genes in four human esophageal squamous cell carcinoma lines. Biosci. Rep. 13:1993;303-312.
48. Yoshida K., Kyo E., Tsuda T. et al. EGF and TGF-α, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int. J. Cancer. 45:1990;131-135.
49. Tsuda T., Tahara E., Kajiyama G. et al. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res. 49:1989;5505-5508.
50. Somers K.D., Cartwright S.L., Schechter G.L. Amplification of the int-2 gene in human head and neck squamous cell carcinomas. Oncogene. 5:1990;915-920.
51. Wagata T., Ishizaki K., Imammura M. et al. Deletion of 17p and amplification of the int-2 gene in esophageal carcinomas. Cancer Res. 51:1991;2113-2117.
52. Kitagawa Y., Ueda M., Ando N. et al. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res. 51:1991;1504-1508.
53. Shiga C., Shiga K., Hirayama K. et al. Prognostic significance of hst-1 gene amplification of primary esophageal carcinomas and its relationship to other prognostic factors. Anticancer Res. 14:1994;651-656.
54. Ikeda Y., Ozawa S., Ando N. et al. Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ann. Thorac. Surg. 62:1996;835-838.
55. Yoshida T., Sakamoto H., Terada M. Amplified genes in cancer in upper digestive tract. Sem. Cancer Biol. 4:1993;33-40.
56. Burgess A.W., Thumwood C.M. The Sixth George Swanson Christie Memorial lecture: growth factors and their receptors: new opportunities for cancer treatment. Pathology. 26:1994;453-463.
57. Issing W.J., Heppt W.J., Kastenbauer E.R. ErbB-3: a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. Eur. Arch. Otorhinolaryngol. 250:1993;392-395.
58. Plowman G.D., Culouscou J.M., Whitney G.S. et al. Ligand-specific activation of HER4/p 180 erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 90:1993;1746-1750.
59. Ozawa S., Ueda M., Ando N. et al. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer. 63:1989;2167-2173.
60. Mukaida H., Toi M., Hirai T. et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer. 68:1991;142-148.
61. Yoshida K., Kuniyasu H., Yasui W. et al. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor α J. Cancer Res. Clin. Oncol. 119:1993;401-407.
62. Itakura Y., Sasano H., Shiga C. et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. Cancer. 74:1994;795-804.
63. Hirai T., Kuwahara M., Yoshida K. et al. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis. Esophagus. 11:1998;221-225.
64. Muller A., Nakagawa H., Rustgi A.K. Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Lett. 113:1997;95-101.
65. Kok T.C., van der Gaast A., Splinter T.A.W. 13-cis-retinoic acid and alpha-interferon in advanced squamous cell cancer of the esophagus. Eur. J. Cancer. 33:1997;165-166.
66. Hickey K., Grehan D., Reid I.M. et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer. 74:1994;1693-1698.
67. Yokota J., Yamamoto T., Toyoshima K. et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 8484:1986;765-767.
68. Mori S., Akiyama T., Morishita Y. et al. Light and electron microscopical demonstration of c-erbB-2 gene product-like immunoreactivity in human malignant tumors. Virchows Arch. B. Cell Pathol. 54:1987;8-15.
69. Chang K., Pastan I., Willingham M.C. Frequent expression of the tumor antigen CAK1 in squamous cell carcinomas. Int. J. Cancer. 51:1992;548-554.
70. Suwanagool P., Parichatikanond P., Maeda S. Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study. Asain. Pac. J. Allergy Immunol. 11:1993;119-122.
71. Shiga K., Shiga C., Sasano H. et al. Expression of c-erbB-2 in human esophageal carcinoma cells: over-expression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res. 13:1993;1293-1302.
72. Suo Z., Su W., Holm R., Nesland J.M. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res. 15:1995;2797-2798.
73. Ikeda Y., Ozawa S., Ando N. et al. Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ann. Thorac. Surg. 62:1996;830-834.
74. Hardwick RH, Barham CP, Ozua, et al. Immunohistochemical detection of p53 and c-erbB-2 in esophageal carcinoma: no correlation with prognosis, Eur J Surg Oncol 1997;23:30-35.
75. Lam K.Y., Tin L., Ma L. c-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur. J. Surg. Oncol. 24:1998;431-435.
76. Hollstein M.C., Peri L., Mandard A.M. et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutation. Cancer Res. 51:1991;4102-4106.
77. Lam K.Y., Shan X.C., Dickens P. et al. The expression of H-ras p21 product in esophageal cancer from Hong Kong Chinese. Am. J. Gastroenterol. 90:1995;171-172.
78. Ono H., Takahashi A., Ogoshi S. Relationship between H-ras p21 product and p53 protein or high risk human papillomaviruses in esophageal cancer from Kochi, Japan. Am. J. Gastroenterol. 89:1994;646-647.
79. Ruol A., Stephens J.K., Michelassi F. et al. Expression of ras oncogene p21 protein in esophageal squamous cell carcinoma. J. Surg. Oncol. 44:1990;142-145.
80. Casson A.G., Wilson S.M., Andrea McCart J. et al. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int. J. Cancer. 72:1997;739-745.
81. Kanda Y., Nishiyama Y., Shimada Y. et al. Analysis of gene amplification and over expression in human esophageal carcinoma cell lines. Int. J. Cancer. 58:1994;291-297.
82. Tsuboi K., Hirayoshi K., Takeuchi K. et al. Expression of the c-myc gene in human gastrointestinal malignaancies. Biochem. Biophys. Res. Comm. 146:1987;699-704.
83. Miyazaki S., Sasano H., Shiga K. et al. Analysis of c-myc oncogene in human esophageal carcinoma: immunohistochemistry, in situ hybridization and Northern and Southern blot studies. Anticancer Res. 12:1992;1747-1756.
84. Zhu D., Wang L., Zhang C. et al. No evidence for the amplification of mdm2 and c-myc genes involved in the genetic susceptibility to esophageal cancer in a high-risk area of north China. Cancer Genet. Cytogenet. 89:1996;184-185.
85. Nakagawa H., Zukerberg L., Togawa K. et al. Human cylin D1 oncogene and esophageal squamous cell carcinoma. Cancer. 76:1995;541-549.
86. Doki Y., Imoto M., Han E.K.H. et al. Increased expression of the p27KIPI protein in human esophageal cancer cell lines that over-express cyclin D1. Carcinogenesis. 18:1997;1139-1148.
87. Jiang W., Kahn S.M., Tomita N. et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 52:1992;2980-2983.
88. Jiang W., Zhang Y.J., Kahn S.M. et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. 90:1993;9026-9030.
89. Tsuruta H., Sakamoto H., Onda M. et al. Amplification and overexpression of EXP1 and EXP2/cyclin D1 genes in human esophageal carcinomas. Biochem. Biophys. Res. Comm. 196:1993;1529-1536.
90. Gramlich T.L., Fritsch C.R., Maurer D. et al. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn. Mol. Pathol. 3:1994;255-259.
91. Adélaide J., Monges G., Dérdérian C. et al. Esophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br. J. Cancer. 71:1995;64-68.
92. Naitoh H., Shibata J., Kawaguchi A. et al. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol. 146:1995;1161-1169.
93. Shinozaki H., Ozawa S., Ando N. et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res. 2:1996;1151-1161.
94. Sheyn I., Noffsinger A.E., Heffelfinger S. et al. Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinoma. Hum. Pathol. 28:1997;270-276.
95. Cheety R., Chetty S. Cyclin D1 and retinoblastoma protein expression in oesophageal squamous cell carcinoma. J. Clin. Pathol. Mol. Pathol. 50:1997;257-260.
96. Takeuchi H., Ozawa S., Ando N. et al. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin. Cancer Res. 3:1997;2229-2236.
97. Roncalli M., Bosari S., Marchetti A. et al. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab. Invest. 78:1998;1049-1057.
98. Inomata M., Uchino S., Tanimura H. et al. Amplification and overexpression of cyclin D1 in aggressive human esophageal cancer. Oncol. Rep. 5:1998;171-176.
99. Shamma A., Doki Y., Shiozaki H. et al. Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int. J. Oncol. 13:1998;455-460.
100. Anayama T., Furihata M., Ishikawa T. et al. Positive correlation between p27KIP1 expression and progression of human esophageal squamous cell carcinoma. Int. J. Cancer Pred. Oncol. 79:1998;439-443.
101. Ishikawa T., Fuihata M., Ohtsuki Y. et al. Cyclin D1 overexpression related to retinoblatoma protein expression as a prognostic marker in human esophageal squamous cell carcinoma. Br. J. Cancer. 77:1998;92-97.
102. Sarbia M., Stahl M., Fink U. et al. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int. J. Cancer Pred. Oncol. 84:1999;86-91.
103. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
104. Lam K.Y., Loke S.L., Chen W.Z. et al. Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese. Eur. J. Surg. Oncol. 21:1995;242-247.
105. Casson A.G., Tammemagi M., Eskandarian S. et al. p53 alterations in esophageal cancer: associated with clinicopathological features, risk factors, and survival. J. Clin. Pathol. Mol. Pathol. 51:1998;71-79.
106. Wagata T., Shibagaki I., Imamura M. et al. Loss of 17p mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 53:1993;846-850.
107. Montesano R., Hollstein M., Hainaut P. Genetic alternations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int. J. Cancer Pred. Oncol. 69:1996;225-235.
108. Wang L.S., Chow K.C., Liu C.C., Chiu J.H. P53 gene alternation in squamous cell carcinoma of the esophagus detected by PCR-cold SSCP analysis. Proc. Natl. Sci. Counc. Repub. China B. 22:1998;114-121.
109. Lam K.Y., Tsao S.W., Zhang D. et al. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinicopatholgical study and survival analysis of 70 patients. Int. J. Cancer. 74:1997;212-219.
110. Bennett W.P., von Brevern M.C., Zhu S.M. et al. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history. Cancer Epidemiol. Biomarkers Prev. 6:1997;963-966.
111. Gaur D., Arora S., Mathur M. et al. High prevalence of p53 gene alterations and protein overexpression in human esophageal cancer: correlation with dietary risk factors in India. Clin. Cancer Res. 3:1997;2129-2136.
112. Shimada H., Nakajima K., Ochiai T. et al. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol. Rep. 5:1998;871-874.
113. Lam K.Y., He D., Ma L. et al. Presence of human papillomavirus in esophageal squamous cell carcinomas of Hong Kong Chinese and its relationship with p53 gene mutation. Hum. Pathol. 28:1997;657-663.
114. Sur M., Cooper K. The role of the human papilloma virus in esophageal cancer. Pathology. 30:1998;348-354.
115. Hamada M., Naomoto Y., Fujiwara T. et al. Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Jpn. J. Clin. Oncol. 26:1996;398-404.
116. Muro K., Ohtsu A., Boku N. et al. Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn. J. Clin. Oncol. 26:1996;65-69.
117. Lam K.Y., Law S., Ma L.T. et al. Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 overexpression predict chemo-responsiveness? Eur. J. Cancer. 33:1997;1221-1225.
118. Ohashi K., Nemoto T., Eishi Y. et al. Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in esophageal squamous cell carcinomas. Virchows Arch. 430:1997;389-395.
119. Seta T., Imazeki F., Yokosuka O. et al. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig. Dis. Sci. 43:1998;279-289.
120. Toh Y., Kuwano H., Sonoda K. et al. Correlation between reduced p21WAF1/CIP1 expression and abnormal p53 expression in esophageal carcinomas. Int. J. Oncol. 11:1997;703-708.
121. Shimoyama S., Konishi T., Kawahara N. et al. Expression and alteration of p53 and p21waf1/cip1 influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology. 45:1998;1497-1504.
122. Yang G., Zhang Z., Liao J. et al. Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int. J. Cancer. 72:1997;746-751.
123. Lam K.Y., Law S., Tin L., Tung P.H.M., Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am. J. Gastroenterol. 52:1999;758-760.
124. Igaki H., Sasaki H., Kishi T. et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem. Biophys. Res. Comm. 203:1994;1090-1095.
125. Liu Q., Yan Y.X., McClure M. et al. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophageal squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 10:1995;619-622.
126. Tanaka H., Shimada Y., Imamura M. et al. Multiple types of aberrations in the p16 (INK4a) and the p15 (INK4b) genes in 30 esophageal squamous cell carcinoma cell lines. Int. J. Cancer. 70:1997;437-442.
127. Kamb A., Gruis N.A., Weaver-Feldhaus J. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
128. Mori T., Miura K., Aoki T. et al. Frequent somatic mutation of the MTS1/CDK4I (mutiple tumor suppressor/cyclin-depedent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54:1994;3396-3397.
129. Zhou X., Tarmin L., Yin J. et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene. 9:1994;3737-3741.
130. Suzuki H., Zhou X., Yin J. et al. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum. Mol. Genet. 4:1995;1883-1887.
131. Esteve A., Martel-Planche G., Sylla B.S. et al. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int. J. Cancer. 66:1996;301-304.
132. Maesawa C., Tamura G., Nishizuka S. et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 56:1996;3875-3878.
133. Muzeau F., Fl(jou J.F., Thomas G. et al. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int. J. Cancer. 72:1997;27-30.
134. Hayashi K., Metzger R., Salonga D. High frequency of simultaneous loss of p16 and p16 β-gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. Oncogene. 15:1997;1481-1488.
135. Chan W.C., Tang C.M.C., Lau K.W. et al. p16 gene tumor suppressor gene mutations in Chinese esophageal carcinomas in Hong Kong. Cancer Lett. 115:1997;201-206.
136. Gamieldien W., Victor T.C., Mugwanya D. et al. p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int. J. Cancer. 78:1998;544-549.
137. Busatto G., Shiao Y.H., Parenti A.R. et al. p16/CDKN2 alternations and pRb expression in esophageal squamous carcinoma. J. Clin. Pathol. Mol. Pathol. 51:1998;80-84.
138. Xing E.P., Nie Y., Wang L.D. et al. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis. 20:1999;77-84.
139. Huang Y., Meltzer S.J., Yin J. et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res. 53:1991;1889-1894.
140. Boynton R.F., Huang Y., Blount P.L. et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res. 51:1991;5766-5769.
141. Ashton-Rickardt P.G., Wyllie A.H., Kovesdi I. et al. MCC, a candidate familial polyposis gene in 5q.21, shows frequent allele loss in colorectal and lung cancer. Oncogene. 6:1991;1881-1886.
142. Boynton R., Blount P.L., Yin J. et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc. Natl. Acad. Sci. 89:1992;3385-3388.
143. Ogasawara S., Maesawa C., Tamura G. et al. Lack of mutations of the adenomatous polyposis coli gene in esophageal and gastric carcinomas. Virchows Arch. 424:1994;607-611.
144. Fearon E.R., Cho K.R., Nigro J.M. et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 247:1990;49-56.
145. Miyake S., Nagai K., Yoshino K. et al. Point mutations and allele deletion of tumor suppressor gene DCC in human esophageal cell carcinomas and their relation to metastasis. Cancer Res. 54:1994;3007-3010.
146. Shibagaki I., Shimada Y., Wagata T. et al. Allelotype analysis of esophageal squamous cell carcinoma. Cancer Res. 54:1994;2996-3000.
147. Mori T., Aoki T., Matsubara T. et al. Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus. Cancer Res. 54:1994;1638-1640.
148. Backer J.M., Mendola C.E., Kovesdi I. et al. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene. 8:1993;497-502.
149. Patel D.D., Bhatavdekar J.M., Chikhlikar P.R. et al. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 esophageal carcinoma: an immunohistochemical approach. J. Surg. Oncol. 65:1997;111-116.
150. Ohbu M., Saegusa M., Okayasu I. Apoptosis and cellular proliferation in esophageal squamous cell carcinomas: differences between keratinzing and nonkeratinizing types. Virchows Arch. 427:1995;271-276.
151. Ohashi K., Nemoto T., Eishi Y. et al. Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in oesophageal squamous cell carcinoma. Virchows Arch. 430:1997;107-115.
152. Hamada M., Naomoto Y., Fujiwara T. et al. Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Jpn. J. Clin. Oncol. 26:1996;398-404.
153. Moreira L.F., Naomoto Y., Hamada M. et al. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res. 15:1995;639-644.
154. Shears L.L., Ribeiro U., Kane J. et al. Apoptosis in esophageal cancer following induction chemoradiotherapy. J. Surg. Res. 79:1998;20-24.
155. Puglisi F., Di Loreto C., Panizzo R. et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the esophagus. J. Clin. Pathol. 49:1996;456-459.
156. Koide N., Koike S., Adachi W. et al. Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus. Surg. Today. 27:1997;685-691.
157. Parenti A.R., Rugge M., Horng Shiao Y. et al. bcl-2 and p53 immunophenotypes in pre-invasive, early and advanced oesophageal squamous cancer. Histopathology. 31:1997;430-435.
158. Ohbu M., Saegusa M., Kobayashi N. et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer. 79:1997;1287-1293.
159. Sarbia M., Bittinger F., Porschen R. et al. bcl-2 expression and prognosis in squamous cell carcinoma of the esophagus. Int. J. Cancer Pred. Oncol. 69:1996;324-328.
160. Sarbia M., Stahl M., Fink U. et al. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin. Cancer Res. 4:1998;2991-2997.
161. Torzewski M., Sarbia M., Heep H. et al. Expression of Bcl-XL, an antiapoptotic marker of the bcl-2 family, in esophageal squamous cell carcinoma. Clin. Cancer Res. 4:1998;577-583.
162. Sarbia M., Bittinger F., Garbellus F. et al. Expression of Bax, a pro-apoptotic member of the bcl-2 family, in esophageal squamous cell carcinoma. Int. J. Cancer. 73:1997;508-513.
163. Yu C.C.W., Filipe M.I. Update on proliferation-associated antibodies applicable to formalin fixed paraffin embedded tissue and their clinical applications. Histochem. J. 25:1993;843-853.
164. Gerdes J., Schwab U., Lemke H. et al. Production of a monoclonal antibody reactive with a human nuclear antigen associated with a human nuclear antigen associated with cell proliferation. Int. J. Cancer. 31:1983;13-20.
165. Lam K.Y., Law S.Y.K., So M.K.P. et al. Prognostic implication of proliferative markers MIB-1 and PC 10 in esophageal sqauamous cell carcinoma. Cancer. 77:1996;7-13.
166. Youssef E.M., Matsuda T., Takada N. et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer. 76:1995;358-366.
167. Sarbia M., Bittinger F., Porschen R. et al. The prognostic significance of tumor cell proliferation in squamous cell carcinomas of the esophagus. Br. J. Cancer. 74:1996;1012-1016.
168. Ikeguchi M., Saito H., Katano K. et al. Correlation between the lymphocytic infiltration of tumors and the proliferative activity of cancer cells from surgically treated esophageal carcinoma. Oncology. 54:1997;311-317.
169. Kawamura T., Goseki N., Koike M. et al. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: immunohistochemical analysis of Ki-67 and p53 antigen in relation to histopathologic findings. Cancer. 77:1996;843-849.
170. Ikeguchi M., Saitou H., Katano K. et al. Biological characteristics of esophageal squamous cell carcinoma associated with contiguous intraepithelial carcinoma. Dis. Esophagus. 10:1997;128-133.
171. Morisaki Y., Yoshizumi Y., Sugiura Y. et al. Prognostic value of proliferating cell nuclear antigen immunostaining using a thermal retrieval technique in esophageal carcinoma. Dis. Esophagus. 9:1996;33-37.
172. Lam K.Y., Ma L., Law S.Y.K. et al. Use of flow cytometry in the analysis of stage III squamous cell carcinoma of the oesophagus and its association with MIB-1. J. Clin. Pathol. 49:1996;975-978.
173. Chanvitan A., Puttawibul P., Casson A.G. Flow cytometry in squamous cell esophageal cancer and precancerous lesions. Dis. Esophagus. 10:1997;206-210.
174. Fakan S., Hernandez-Verdan D. The nucleolus and the nucleolar organizer regions. Biol. Cell. 56:1986;189-206.
175. Yoshida Y., Okamura T., Ezaki T. et al. Predictors of post-operative distant recurrences in esophageal carcinoma. Ann. Thorac. Surg. 57:1994;886-889.
176. Kuwano H., Sumiyoshi K., Nozoe T. et al. The prognostic significance of the cytophotometric DNA content and its relationship with the argrophilic nucleolar organizer regions (AgNOR) and proliferating cell nuclear antigen (PCNA) in esophageal cancer. Eur. J. Surg. Oncol. 21:1995;368-373.
177. Morisaki Y., Shima S., Yoshizumi Y. et al. PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis. Surg. Today. 25:1995;389-395.
178. Katz A.M., Rosenthal D., Sauder D.N. Cell adhesion molecules: structure, function, and implication in a variety of cutaneous and other pathologic
179. Streit M., Schmidt R., Hilgenfeld R.U. et al. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Recent Results Cancer. Res. 142:1996;19-50.
180. Dobson H., Pignatelli M., Hopwood D. et al. Cell adhesion molecules in esophageal epithelium. Gut. 35:1994;1343-1347.
181. Smith M.E.F., Pignatelli M. The molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology. 31:1997;107-111.
182. Kadowaki T., Shiozaki H., Inoue M. et al. E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res. 54:1994;291-296.
183. Takayama T., Shiozaki H., Shibamoto S. et al. β-catenin expression in human cancers. Am. J. Pathol. 148:1996;39-46.
184. Tamura S., Shiozaki H., Miyata M. et al. Decreased E-cadherin expression is associated with hematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the esophagus. Br. J. Surg. 83:1996;1608-1614.
185. Jian W.G., Darnton S.J., Jenner K. et al. Expression of E-cadherin in oesophageal carcinomas from the UK and China: disparities in prognostic significance. J. Clin. Pathol. 50:1997;640-644.
186. Sanders D.S., Bruton R., Darnton S.J. et al. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int. J. Cancer. 79:1998;573-579.
187. Natsugoe S., Mueller J., Stein H.J. et al. Micrometastasis and tumor cell microinvolvment of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer. 83:1998;858-866.
188. Kimura Y., Shiozaki H., Doki Y. et al. Cytoplasmic beta-catenin in esophageal cancers. Int. J. Cancer. 84:1999;174-178.
189. Nakanishi Y., Ochiai A., Akimoto S. et al. Expression of E-cadherin, α-catenin, β-catenin and plakoglobulin in esophageal carcinomas and its prognostic significance. Oncology. 54:1997;158-165.
190. Natsugoe S., Mueller J., Kijima F. et al. Extranodal connective tissue invasion and the expression of desmosomal glycoprotein 1 in squamous cell carcinoma of the esophagus. Br. J. Cancer. 75:1997;892-897.
191. Nakano S., Baba M., Natsugoe S. et al. Detection of lymph nodes metastasis using desmoglein I expression in superficial esophageal cancer in relation to the endoscopic mucosal resection. Dis. Esophagus. 11:1998;157-161.
192. Tanabe K.K., Saya H. The CD44 adhesion molecule and metastasis. Crit. Rev. Oncog. 5:1994;201-212.
193. Roye G.D., Myers R.B., Brown D. et al. CD44 expression in dysplastic epithelium and squamous cell carcinoma of the esophagus. Int. J. Cancer Pred. Oncol. 69:1996;254-258.
194. Rockett J.C., Darnton S.J., Crocker J. et al. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in esophageal carcinoma. J. Clin. Pathol. 48:1995;539-544.
195. Rockett J.C., Darnton S.J., Crocker J. et al. Lymphocyte infiltration in esophageal carcinoma: lack of correlation with MHC antigens, ICAM-1, and tumor stage and grade. J. Clin. Pathol. 49:1996;264-267.
196. Hosch S.B., Izbicki J.R., Pichlmeier U. et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int. J. Cancer. 74:1997;582-587.
197. Shima I., Sasaguri Y., Kusukawa J. et al. Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human esophageal squamous cell carcinoma in response to epidermal growth factor. Br. J. Cancer. 67:1993;721-727.
198. Torzewski M., Sarbia M., Verreet P. et al. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin. Cancer Res. 3:1997;2263-2268.
199. Baba K., Kuwano H., Kitamura K. et al. Carcinomatous invasion and lymphocyte infiltration in early esophageal carcinoma with special regard to basement membrane: an immunohistochemical study. Hepatogastroenterology. 40:1993;226-231.
200. Birkedal-Hansen H., Moore W.G., Bodden M.K. et al. Matrix metalloproteinase: a review. Crit. Rev. Oral Biol. Med. 4:1993;197-250.
201. Matrisian L.M., Leroy P., Ruhlmann C. et al. Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rate fibroblasts. Mol. Cell. Biol. 6:1986;1679-1686.
202. Shima I., Sasaguri Y., Kusukawa J. et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. Cancer. 70:1992;2747-2753.
203. Porte H., Pierre T., Kotelevets L. et al. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res. 4:1998;1375-1382.
204. Murray G., Duncan M.E., O'Neil P. et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185:1998;256-261.
205. Adachi Y., Itoh F., Yamamoto H. et al. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int. J. Oncol. 13:1998;1031-1035.
206. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6:1995;967-974.